Khan, Niaz E.
Al Shaikh, AbdulRahman A. M.
Hassoun, Ahmed A. K.
Hassan, Amr M.
Salah, Mona M.
Al Abdella, Nabeela A.
Safarini, Saher S. M.
Al Dahi, Waleed A.
Akil, Yasser A. http://orcid.org/0000-0002-1472-6721
Clinical trials referenced in this document:
Documents that mention this clinical trial
Real-World Study on Effectiveness of Insulin Glargine U300 After Oral Antidiabetic Drug Failure in Patients with Type 2 Diabetes in the Gulf Region
https://doi.org/10.1007/s13300-024-01537-2
1028-P: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (gla-300) in Insulin-Naïve Patients with Type 2 Diabetes (T2DM): Interim Analysis of the ATOS Study
https://doi.org/10.2337/db20-1028-p
Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study
https://doi.org/10.1007/s13300-022-01266-4
Funding for this research was provided by:
Sanofi
Article History
Received: 24 November 2023
Accepted: 19 January 2024
First Online: 15 February 2024
Declarations
:
: Amr M. Hassan and Yasser A. Akil are Sanofi employees, with financial interests in the Company. Authors Niaz E. Khan, AbdulRahman A. M. Al Shaikh, Ahmed A. K. Hassoun, Mona M. Salah, Nabeela A. Al Abdella, Saher S. M. Safarini, and Waleed A. Al Dahi declare no conflict of interest.
: The Institutional Review Board of King Abdulaziz University in Saudi Arabia (Reference number 17-18) has approved this study. All patients signed an informed consent form before any study-related activity. The study was conducted in accordance with the principles laid down by the 18th World Medical Assembly (Helsinki, 1964), and its latest amendments.